Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colaren
- Development stage
- Phase 3
- Lead developer
- Universidad de Guadalajara
- Administration
- Oral
01
Overview
**Colaren** is a proprietary dietary supplement whose composition and manufacturer were not publicly specified in the available trial record. It was evaluated by the University of Guadalajara as an adjunct to annual 4 mg zoledronic acid for secondary osteoporosis in HIV-positive and HIV-negative men. The registered study compared zoledronic acid plus Colaren with zoledronic acid plus conventional calcium and vitamin D supplementation. No specific pharmacologic target, active ingredient, or mechanism of action for Colaren was disclosed in the public record, and it should not be conflated with zoledronic acid or the comparator calcium and vitamin D supplements.
- Brand names
- Colaren
- Other names
- Colaren
Beyond the preview
Go deeper on Colaren.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Colaren.